Skip to main content
Caplight Logo









Shanghai Best-Link Bioscience

Shanghai Best-Link Bioscience

Private
ShanghaiHealthcare & Life Scienceshttp://bestlinkbio.com/

Last Round

Series C

May 15, 2026

Total Funding Raised

$153.39M

Company Overview

Shanghai Best-Link Bioscience is a biotechnology company that develops innovative drugs for tumor therapy using its proprietary nano-conjugate drug platform (NMPDC®).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

nano-conjugate drugNMPDConcologytumor immunotherapyprecision drug deliverysolid tumor treatmentADCbiotechantibody-drug conjugatesdrug licensingclinical-stage biotechtargeted therapydrug pipelinenanomedicinebiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Best-Link Bioscience Comparables

Compare Shanghai Best-Link Bioscience with similar companies based on industry and business-model similarity.

Shanghai Best-Link Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tianjin Conjustar Biotechnology Co., Ltd.
84%
RS Research
83%
Cybrexa Therapeutics
81%

Shanghai Best-Link Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CMay 15, 2026
Series BJan 28, 2026
Series BJan 28, 2024
Series AApr 8, 2023
AngelJun 10, 2021

Shanghai Best-Link Bioscience Investors

Notable investors and investment history

Shanghai Best-Link Bioscience investors
InvestorRounds
Tianjin TEDA Science and Technology Investment Co., Ltd.Series B
Lapam CapitalSeries B, Series A
Tigeryeah CapitalSeries B, Series A
CAS StarSeries B
Yonghua CapitalSeries B
Hyfinity InvestmentsSeries A

Shanghai Best-Link Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Best-Link Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Best-Link Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2021
Last FundingMay 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?